Lyell Immunopharma raises $80m to fund ronde-cel BLA push
Lyell Immunopharma has closed an $80 million private placement to fund the late-stage development of rondecabtagene autoleucel (ronde-cel), its dual-targeting CD19/CD20 CAR T-cell candidate for relapsed or refractory large B-cell lymphoma. The Nasdaq-listed company sold approximately 7.4 million shares at $10.77 each, matching the prior day's closing price. Goldman Sachs and Leerink Partners acted as placement agents.
Investors in the round include ARCH Venture Partners, Adage Capital Management, Caligan Partners and RTW Investments, alongside an unnamed leading mutual fund and a mix of new and existing institutional backers. The proceeds are expected to extend Lyell's cash runway into 2028, taking it beyond the anticipated BLA submission to the US Food and Drug Administration in the second half of 2027.
Ronde-cel's regulatory path
Ronde-cel is currently being evaluated in two pivotal studies. PiNACLE is a single-arm trial in the third-line-or-later LBCL setting, designed to support an initial BLA filing for regular marketing approval. The companion PiNACLE-H2H study is a randomised Phase 3 trial comparing ronde-cel head-to-head with an investigator's choice of approved CD19-directed CAR T-cell therapy in the second-line setting. Lyell expects to present updated data from PiNACLE at the American Society of Hematology Annual Meeting in December 2026, with the full pivotal dataset anticipated in mid-2027.
The candidate holds Regenerative Medicine Advanced Therapy and Fast Track designations from the FDA for diffuse LBCL in both the third-line-or-later and second-line settings, designations that can accelerate agency review and facilitate earlier regulatory dialogue.
Smital Shah, Chief Financial and Business Officer, said the financing "strengthens our financial position and supports the execution of our strategy as we approach several important clinical and regulatory milestones," adding that ronde-cel's potential for durable responses as a one-time outpatient treatment represents a "significant clinical and commercial opportunity."
The raise also provides runway for LYL273, Lyell's GCC-targeted CAR T-cell candidate in metastatic colorectal cancer, which is progressing toward a recommended Phase 2 dose selection. An End-of-Phase 1 meeting with the FDA and additional clinical data are expected in 2027.
Market context
The LBCL CAR T-cell market is already populated by approved products from Kite Pharma (a Gilead unit), Bristol Myers Squibb and Novartis, all of which target CD19. Ronde-cel's dual CD19/CD20 targeting is intended to address antigen escape, a recognised mechanism of treatment failure with single-target approaches. Whether that mechanistic rationale translates into superior durable response rates in a randomised setting is the central clinical question PiNACLE-H2H will need to answer.
Lyell also highlights LyFE, its in-house manufacturing platform, which the company says has the capacity to produce more than 3,000 CAR T-cell doses per year. Manufacturing scale and consistency have been recurring commercial bottlenecks across the CAR T sector; a credible internal manufacturing capability is therefore an increasingly important part of any BLA package and commercial readiness narrative.
With pivotal data due in mid-2027 and a BLA submission targeted for the second half of that year, Lyell's next twelve months will be closely watched by investors assessing whether a next-generation dual-targeting approach can carve out a durable position in an intensely competitive segment.